Market News
Recent Developments
New product launches
- On June 21, 2023, Cardio Diagnostics Holdings, Inc, a pioneer in AI-driven precision cardiovascular medicine tests, announced the U.S. launch of PrecisionCHD. This groundbreaking test marks a significant milestone in the fight against coronary heart disease (CHD), the most common type of heart disease and the primary cause of heart attacks. It is the second product to be released from Cardio Diagnostics' cutting-edge suite of AI-driven molecular cardiovascular disease technologies.
- On June 20, 2023, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND (Biomarker Isolation and N-richment for Detection) technology. With millions of assays conducted daily in clinical laboratories worldwide, the search for specific biomarkers to identify early-stage diseases is becoming increasingly crucial. However, the inherent challenges posed by diverse patient sample types, including urine, saliva, and blood, can lead to false positive or negative results. VeraBINDing the sample during collection or preparation transforms complex samples into a matrix-free sample which enhances the performance of on-market tests and can allow healthcare professionals to realize a significant breakthrough in biomarker detection.
- On February 28, 2023, Cardio Diagnostics Holdings announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. PrecisionCHD is the second clinical test that uses its artificial intelligence (AI)-enabled Integrated Epigenetic-Genetic Engine. The test uses epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers with a machine-learning model developed by analyzing billions of genomic and epigenomic data points.
Acquisition and partnerships
- On July 12, 2023, BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, announced that the company has signed a collaborative agreement with Grupo Terralpe, Inc., a renowned private investment group based in Mexico City and Boston, Mass, U.S. Together, the companies will commercialize the pstateDx test, BPGbio's prostate cancer diagnostic test, in Mexico, U.S. BPGbio's pstateDx test is the first diagnostic product discovered by the company's AI-powered Interrogative Biology platform to be commercially launched. The pstateDx test is a non-PSA based, unique molecular diagnostic blood test that measures filamin A, a key biological driver of prostate cancer.
- On July 11, 2023, Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary be.well technology platform, launched a web-based partner portal and suite of enablement software tools to further drive innovative partnerships onto the platform to co-develop and commercialize rapid, point of need diagnostic solutions across multiple life sciences industry sectors. Furthermore, its newest partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI extends the platform into the large animal veterinary sector. The institute belongs to the Fraunhofer-Gesellschaft, the world’s leading applied research organization.
- In February 2021, S.R.L. Diagnostics, a diagnostics chain with the largest accredited lab network, has linked an agreement with the U.S.-based Mayo Clinic Laboratories. The collaboration aims to facilitate initiatives between the two organizations to help physicians maintain lifelong knowledge and skills for safe clinical practice.
U.S.: 
U.K. : 
India :